TOP TEN perturbations for NM_000266 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000266
Selected probe(set): 206022_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000266 (206022_at) across 5392 perturbations tested by GENEVESTIGATOR:

monocyte activation study 1 (NOD2L/TLR/1L; 6h) / untreated monocyte sample (6h)

Relative Expression (log2-ratio):6.5252924
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and collected after 6 hours for RNA isolation.

monocyte activation study 1 (TLR/1L; 6h) / untreated monocyte sample (6h)

Relative Expression (log2-ratio):6.1147413
Number of Samples:5 / 5
Experimental monocyte activation study 1 (TLR/1L; 6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and collected after 6 hours for RNA isolation.

monocyte activation study 1 (NOD2L; 6h) / untreated monocyte sample (6h)

Relative Expression (log2-ratio):5.643176
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L; 6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 6 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells.
Control untreated monocyte sample (6h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and collected after 6 hours for RNA isolation.

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):5.4636
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 ? 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

monocyte activation study 1 (NOD2L; 24h) / untreated monocyte sample (24h)

Relative Expression (log2-ratio):5.1258535
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells.
Control untreated monocyte sample (24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample

Relative Expression (log2-ratio):5.0418215
Number of Samples:7 / 12
Experimental IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

monocyte activation study 1 (NOD2L/TLR/1L; 24h) / untreated monocyte sample (24h)

Relative Expression (log2-ratio):4.9947634
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

glioma study 16 (LN-215) / normal astrocyte sample

Relative Expression (log2-ratio):-4.748129
Number of Samples:2 / 3
Experimental glioma study 16 (LN-215)
Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37?C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

VTX-2337 study 1 / untreated monocyte sample

Relative Expression (log2-ratio):4.4360585
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control untreated monocyte sample
Peripheral blood monocytes isolated from healthy donors.

LPS study 1 / vehicle (DTT/polym. B) treated monocyte sample

Relative Expression (log2-ratio):4.3957787
Number of Samples:3 / 3
Experimental LPS study 1
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, Lipopolysaccharide (LPS; 100 ng/ml) was added. At 18 h after treatment, total RNA was isolated. ATC code:---
Control vehicle (DTT/polym. B) treated monocyte sample
Monocytes were plated in 12-well plates and differentiated in RPMI 1640 containing 10% FBS plus 50 ng/ml (>500 U/ml) GM-CSF and 100 ng/ml (>500 U/ml) IL-4 for 5 days. At day 5, vehicle consisting of equivalent volume of 8 mM DTT (galectin-1 storage buffer) and 10 ?g/ml polymyxin B was added. At 18 h after treatment, total RNA was isolated.